Reply

Sharon A. Chung; Philip Seo; Peter A. Merkel; Carol A. Langford

doi:10.1002/art.41991

Reply

Sharon A. Chung, Philip Seo, Peter A. Merkel, Carol A. Langford

School of Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

We appreciate the insights and concerns shared by Dr. Jain et al. regarding the use of rituximab (RTX) and cyclophosphamide (CYC) for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), as outlined in the American College of Rheumatology/Vasculitis Foundation (ACR/VF) guideline for the treatment of ANCA-associated vasculitis (AAV) [1]. These concerns are timely given the ongoing COVID-19 pandemic.

Original language	English (US)
Pages (from-to)	545-546
Number of pages	2
Journal	Arthritis and Rheumatology
Volume	74
Issue number	3
DOIs	https://doi.org/10.1002/art.41991
State	Published - Mar 2022

ASJC Scopus subject areas

Immunology and Allergy
Rheumatology
Immunology

Access to Document

10.1002/art.41991

Cite this

@article{4f99297d960a48ab9d5fbca1e4bc66dc,

title = "Reply",

abstract = "We appreciate the insights and concerns shared by Dr. Jain et al. regarding the use of rituximab (RTX) and cyclophosphamide (CYC) for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), as outlined in the American College of Rheumatology/Vasculitis Foundation (ACR/VF) guideline for the treatment of ANCA-associated vasculitis (AAV) [1]. These concerns are timely given the ongoing COVID-19 pandemic.",

author = "Chung, {Sharon A.} and Philip Seo and Merkel, {Peter A.} and Langford, {Carol A.}",

year = "2022",

month = mar,

doi = "10.1002/art.41991",

language = "English (US)",

volume = "74",

pages = "545--546",

journal = "Arthritis and Rheumatology",

issn = "2326-5191",

publisher = "John Wiley and Sons Ltd",

number = "3",

}

TY - JOUR

T1 - Reply

AU - Chung, Sharon A.

AU - Seo, Philip

AU - Merkel, Peter A.

AU - Langford, Carol A.

PY - 2022/3

Y1 - 2022/3

N2 - We appreciate the insights and concerns shared by Dr. Jain et al. regarding the use of rituximab (RTX) and cyclophosphamide (CYC) for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), as outlined in the American College of Rheumatology/Vasculitis Foundation (ACR/VF) guideline for the treatment of ANCA-associated vasculitis (AAV) [1]. These concerns are timely given the ongoing COVID-19 pandemic.

AB - We appreciate the insights and concerns shared by Dr. Jain et al. regarding the use of rituximab (RTX) and cyclophosphamide (CYC) for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), as outlined in the American College of Rheumatology/Vasculitis Foundation (ACR/VF) guideline for the treatment of ANCA-associated vasculitis (AAV) [1]. These concerns are timely given the ongoing COVID-19 pandemic.

UR - http://www.scopus.com/inward/record.url?scp=85118476295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85118476295&partnerID=8YFLogxK

U2 - 10.1002/art.41991

DO - 10.1002/art.41991

M3 - Comment/debate

C2 - 34605229

AN - SCOPUS:85118476295

SN - 2326-5191

VL - 74

SP - 545

EP - 546

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

IS - 3

ER -

Reply

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this